Clinical Trial Update: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial evaluating the combination of camrelizumab and palbociclib for resectable esophageal squamous cell carcinoma, currently not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Palbociclib (palbociclib)

Snippet

Sponsor: West China Hospital | Conditions: Esophageal Squamour Cell Cancer | Phase 2 | Status: NOT_YET_RECRUITING